Its primary pharmacodynamic action is believed to involve activation of the AMP-activated protein kinase (AMPK) pathway, which enhances insulin sensitivity and improves peripheral insulin resistance in patients with T2DM—an axis potentially critical to maintaining cerebral glucose homeostasis. This evidence concerns the gene INS and type 2 diabetes mellitus.